文献速递分子诊断临床微生物

从三重到四重:罗氏Cobas Liat SARS-CoV-2、流感A/B及RSV检测试剂盒诊断准确性评估

From triplex to tetraplex: evaluation of the diagnostic accuracy of the new Roche Cobas Liat SARS-CoV-2, influenza A/B & RSV assay.
PubMed 文献 · J Clin Microbiol · 2026-07-20

在芬兰Tampere大学医院开展观察性诊断准确性研究,用315份鼻咽拭子样本评估新型Cobas Liat四重检测试剂盒,并与分子诊断参考方法比较。结果显示该试剂盒对流感A、流感B、SARS-CoV-2和RSV的敏感性均为100%,特异性分别为98.5%、99.7%、98.2%和97.0%。该试剂盒适合用于即时检测和实验室检测。

要点

  • Cobas Liat四重检测对流感A/B、SARS-CoV-2和RSV的敏感性均为100%。
  • 特异性分别为流感A 98.5%、流感B 99.7%、SARS-CoV-2 98.2%、RSV 97.0%。
  • 四重检测可减少儿科急诊双重检测,成人急诊可提高RSV诊断检出率。

核心结论

  • Cobas Liat四重检测试剂盒具有极佳的临床和分析准确性,适合即时检测和实验室检测。

研究设计与样本

  • 观察性诊断准确性研究,在芬兰Tampere大学医院纳入315份临床鼻咽拭子样本,以分子诊断方法为参考标准。

主要发现

  • 流感A敏感性100%、特异性98.5%;流感B敏感性100%、特异性99.7%;SARS-CoV-2敏感性100%、特异性98.2%;RSV敏感性100%、特异性97.0%。
  • 在指数检测和参考检测中,Cobas Liat对流感A、SARS-CoV-2和RSV的分析敏感性最高。
  • 未观察到与 panel 外微生物的交叉反应。

关键数值与推荐

  • 敏感性:流感A 100%、流感B 100%、SARS-CoV-2 100%、RSV 100%。
  • 特异性:流感A 98.5%、流感B 99.7%、SARS-CoV-2 98.2%、RSV 97.0%。

临床怎么用

  • 在儿科急诊,使用四重检测可替代两种三重检测,可能降低成本和人工操作。
  • 在成人急诊,四重检测可能显著提高RSV的诊断检出率,而RSV在成人急诊即时检测中覆盖率低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rapid and accurate diagnostics of epidemic respiratory viruses are relevant for optimal care pathways. In this observational diagnostic accuracy study, the novel Cobas Liat assay (Roche Molecular Systems) was evaluated for the detection of SARS-CoV-2, influenza A and B, and respiratory syncytial virus (RSV) in the clinical setting of Tampere University Hospital, Tampere, Finland. In addition, the added value of the tetraplex assay instead of two partially overlapping triplex assays (influenza A/B and SARS-CoV-2 or RSV) was assessed in the context of adult and pediatric emergency department (AED, PED) point-of-care (PoC) testing environments. A total of 315 clinical nasopharyngeal swab samples were analyzed. Diagnostic accuracy was evaluated against a molecular diagnostic reference. The evaluated Cobas Liat assay had sensitivities and specificities of 100% and 98.5% for influenza A, 100% and 99.7% for influenza B, 100% and 98.2% for SARS-CoV-2, and 100% and 97.0% for RSV, respectively. Among the index and reference tests, the Cobas Liat assay demonstrated the highest analytical sensitivity for influenza A, SARS-CoV-2, and RSV. No cross-reactivity with off-panel microbes was observed. With respect to clinical applicability, implementation of the evaluated tetraplex test would decrease double testing with two triplex tests in PED, likely decreasing costs and hands-on work. In AED, tetraplex testing would likely significantly increase the diagnostic yield for RSV, only rarely covered by PoC testing in AED. The evaluated Cobas Liat assay had excellent clinical and analytical accuracy, being highly suitable for PoC use but also for laboratory-based testing of influenza viruses, SARS-CoV-2, and RSV.IMPORTANCEUntil recently, rapid point-of-care diagnostics have been somewhat limited by triplex four-channel analysis technology, separating four of the most important epidemic respiratory viruses-influenza A, influenza B, respiratory syncytial virus, and SARS-CoV-2-into two individual triplex tests. The evaluated tetraplex respiratory viral assay combines the two partially overlapping tests into a single test, streamlining analysis in two-test settings and potentially reducing diagnostic gaps in one-test settings. To our knowledge, this is the first study to describe the diagnostic accuracy of the novel Cobas Liat SARS-CoV-2, influenza A/B, and respiratory syncytial virus (RSV) assay with additional considerations for analytical sensitivity and specificity, and clinical utility in adult and pediatric emergency department use.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Luukinen B, Lång M, Peltola M, et al. From triplex to tetraplex: evaluation of the diagnostic accuracy of the new Roche Cobas Liat SARS-CoV-2, influenza A/B & RSV assay. J Clin Microbiol. 2026. PMID: 42474354. doi:10.1128/jcm.00274-26

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。